Snapshot from Jun 10, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Diasome presents positive OPTI-2 results
Tech clinical trial results

Diasome presents positive OPTI-2 results

Analysis based on 6 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 2b clinical trial results for HDV-Insulin Lispro could significantly boost investor confidence in Diasome Pharmaceuticals, potentially leading to increased valuation and future investment. This development could also impact the broader pharmaceutical market by introducing a new, potentially superior treatment for type 1 diabetes, affecting companies with existing diabetes therapies.

Biotechnology Pharmaceuticals
Event Summary

Diasome Pharmaceuticals announced that results from its OPTI-2 Phase 2b clinical trial for HDV-Insulin Lispro will be presented at the American Diabetes Association's 86th Scientific Sessions. The trial, conducted across 27 sites in the United States with 226 adults with type 1 diabetes, showed that HDV-Insulin Lispro reduces hypoglycemia risk compared to standard insulin lispro. Robert Geho, CEO of Diasome Pharmaceuticals, highlighted the potential of this hepatocyte-directed insulin to improve diabetes management by restoring a more physiologic pattern of hepatic insulin exposure. Klara Klein will present the detailed findings on June 7, 2026. HDV-Insulin Lispro is an investigational therapy not yet approved by the United States — Food and Drug Administration.

Key Actions
90 Diasome Pharmaceuticals announced presentation of results American Diabetes Association
80 Klara Klein will present data
Entities Involved
priv
Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company that developed HDV-Insulin Lispro and will present positive Phase 2b clinical trial results, which could significantly advance its lead insulin program and enhance its market position.
Importance 100 Sentiment 70
ngo
American Diabetes Association
The American Diabetes Association is hosting its 86th Scientific Sessions where Diasome Pharmaceuticals will present its OPTI-2 Phase 2b clinical trial results.
Importance 40 Sentiment 0
per
Robert Geho
Robert Geho, CEO of Diasome Pharmaceuticals, expressed optimism about the potential of HDV-Insulin Lispro to improve diabetes management.
Importance 30 Sentiment 0
per
Klara Klein
Klara Klein, a Principal Investigator, will present the OPTI-2 data at the American Diabetes Association's Scientific Sessions.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
HDV-Insulin Lispro is an investigational therapy and has not yet been approved by the United States — Food and Drug Administration.
Importance 10 Sentiment 0
cnt
United States
The OPTI-2 trial was conducted at 27 sites within the United States.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.